Get started
Author

Henry S. Ngu

Observed names: H. Ngu, Henry Ngu
ORCID: 0000-0001-5773-4847
Observed ORCID: 0000-0001-5773-4847
OpenAlex ID: A5067856972
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma
2023 · Laura K. Hilton, Henry S. Ngu, et al. · Journal of Clinical Oncology · 64
PDF
Revising the Treatment Pathways in Lymphoma: New Standards of Care—How Do We Choose?
2022 · Henry Ngu, Radhika Takiar, et al. · American Society of Clinical Oncology Educational Book · 18
PDF
Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas
2023 · Henry S. Ngu, Kerry J. Savage · Haematologica · 17
PDF
Frontline Management of Nodal Peripheral T-Cell Lymphomas
2023 · Henry S. Ngu, Kerry J. Savage · American Society of Clinical Oncology Educational Book · 5
PDF
Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology
2021 · Henry S. Ngu, Laura K Hilton, et al. · Blood · 4
Heterozygous germline TET2 loss‐of‐function variants associated with an ALPS ‐like phenotype
2025 · Sean Harrop, Joshua Casan, et al. · British Journal of Haematology · 2
Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL
2022 · Laura K Hilton, Henry S. Ngu, et al. · Blood · 2
TCL-323 Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) With Intention for Curative Therapy Incorporating High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)
2022 · Henry Ngu, Stephen Parkin, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) with Intention for Curative Therapy Incorporating High Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)
2021 · Henry S. Ngu, Stephen Parkin, et al. · Blood · 1
Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma
2025 · Fei Li, Stephen Opat, et al. · Blood
PDF
725 | Conventional Chemotherapy Remains Effective in Relapsed and Primary Refractory Classical Hodgkin Lymphoma in the Era of Novel Agents: a Single‐institution Experience
2025 · M. L. Tan, S. H. Wong, et al. · Hematological Oncology
PDF
Long-Term Outcomes of Patients Aged 65 Years or Older with Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) and T-Follicular Helper T-Cell Lymphoma (TFHTCL) Treated with Curative Intent CHOP(like) Chemotherapy
2022 · Henry S. Ngu, Diego Villa, et al. · Blood
Poster: TCL-323 Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) With Intention for Curative Therapy Incorporating High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)
2022 · Henry Ngu, Stephen Parkin, et al. · Clinical Lymphoma Myeloma & Leukemia
Pb2138 Light Chain (al) Amyloidosis: a Single Centre Experience and the Effectiveness of Bortezomib Based Therapy as First Line Therapy
2019 · H. Ngu, D. Simpson, et al. · HemaSphere
Works count: 14
Citation count: 115
H-index: 4
I10-index: 3
Year
Topic
Type